Sonnet BioTherapeutics Holdings, Inc. Gains 86.73%
Sonnet BioTherapeutics Holdings, Inc. (SONN:NASDAQ) jumped higher at $0.52, a gain of 86.7%. On Tue, Mar 15, 2022, SONN:NASDAQ hit a New 2-Week Intraday Low of $0.27. The stock got featured on our News Catalysts scanner on Wed, Mar 16, 2022 at 07:52 AM in the 'BIOTECH' category. From Tue, Mar 01, 2022, the stock recorded 30.00% Up Days and 27.27% Green Days
The stock spiked on Wed, Mar 02, 2022 at $0.37 with a volume of 5M+.
About Sonnet BioTherapeutics Holdings, Inc. (SONN:NASDAQ)
Sonnet BioTherapeutics Holdings Inc is a biotechnology company engaged in the development of biologic drugs focused on human antibody binding technology. The firm's pipeline products include SON-080 (low-dose IL-6), SON-081 (low dose IL-6), SON-1010 (IL12-FHAB), and others.
Top 10 Gainers:
- HCM Acquisition Corp (HCMA:NASDAQ), 100%
- Sonnet BioTherapeutics Holdings, Inc. (SONN:NASDAQ), 86.73%
- 21Vianet Group, Inc. (VNET:NASDAQ), 83.25%
- Zhihu Inc. American Depositary Shares (every two of each representing one Class A) (ZH:NYSE), 79.17%
- Kingsoft Cloud Holdings Limited (KC:NASDAQ), 72.27%
- Dingdong (Cayman) Limited American Depositary Shares (each two representing three) (DDL:NYSE), 66.67%
- JOYY Inc. (YY:NASDAQ), 66.35%
- KE Holdings Inc American Depositary Shares (each representing three Class A) (BEKE:NYSE), 64.35%
- DouYu International Holdings Limited (DOYU:NASDAQ), 60.56%
- Chindata Group Holdings Limited (CD:NASDAQ), 60.3%